( 您好!臺灣時間:2021/07/27 18:10
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果 :::


研究生(外文):Tsun- Hsiang Yang
論文名稱(外文):Thermal ablation by Electromagnetic Heating Needles on Small Animal Tumors- A Pilot Study
指導教授(外文):Jih Jong Lee
外文關鍵詞:electromagnetic therapythermal ablationhyperthermiasmall animal tumorsheating needles
  • 被引用被引用:0
  • 點閱點閱:204
  • 評分評分:
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:0
熱消融在人類腫瘤的局部控制中已使用數年。相對於傳統外科手術來說,熱消融主要的優點更加快速,導致更少的出血量,以及最重要的是,能夠用非侵入性的方式使用因而大幅降低對於周遭鄰近組織的傷害。電磁熱療法(EMT)是由成功大學所新開發的一種新穎熱消融治療系統。這項新穎治療的優勢在於較便宜的成本因為針具是用間接加熱的方式而且是可拋棄式的,並且沒有對用於探針的數量的限制。在這個研究中,共有10例患者包括11個腫瘤納入此研究。腫瘤類型包括6個肉瘤、4個上皮腫瘤、以及1個圓形細胞瘤。腫瘤治療療效的部分有8個腫瘤 (73%) 達到完全消退以及3個 (27%) 部分消退。此治療方式的併發症較不嚴重但皮膚以及軟組織傷害是可被預期的。治療之後術區將會形成開放性傷口,但此傷口並不會有出血、疼痛、以及其他副作用且在一般護理之將在1.5個月後癒合。在理想的情況下,藉由這項新穎治療的優點、低技術要求和確切的療效,能夠在未來將使更多的動物受益。

Thermal ablation has been used for local control of human neoplasm for several years. The main advantages of thermal ablation are shorter operation time, less hemorrhage than traditional surgical procedures, and most importantly, can be performed minimal invasively with little damage to adjacent tissue. Electromagnetic thermal therapy (EMT) is a new treatment system that is relatively inexpensive and does not have a limit on the total number of heating-needles used. A total of 10 patients and 11 tumors were enrolled into the study. Tumor types included 6 sarcomas, 4 epithelial tumors, and 1 round cell tumor. In terms of tumor efficacy, 8 CR (73%) and 3 PR (27%) were achieved. Complications post therapy was acceptable although dermatological and soft tissue damages were inevitable but manageable. Open wound is expected in most cases after the treatment but without hemorrhage, pain, or other complications. The wounds undergo second-intentional healing approximately 1.5 months post-treatment procedure depending on original tumor size. Ideally, with its advantages and low technique requirements, this novel therapy/device will benefit more cancer bearing animals in the future.

致謝 ii
中文摘要 iv
Abstract v
List of Tables ix
Chapter I Introduction 1
Chapter II Literature review 4
2.1 The Background of Thermal Ablation of tumors 5
2.2 Mechanism of EMT 6
2.3 Needle placement and temperature distribution 7
2.4 The Effect of Temperature on cells and zones of ablation 8
2.5 Immune response 9
2.6 Adjuvant therapy 10
2.7 Superficial Tumors 11
2.7.1 Squamous cell carcinoma (SCC) 11
2.7.2 Perianal adenoma 11
2.7.3 Feline injection site sarcoma (FISS) 12
2.7.4 Fibrosarcoma 12
2.7.5 Peripheral nerve sheath tumor (PNST) 13
2.7.6 Mast cell tumor (MCT) 13
2.7.7 Mammary gland tumor (MGT) 14
2.8 Visceral tumor 15
2.8.8 Hepatocellular carcinoma (HCC) 15
Chapter III Aim 16
Chapter IV Materials and Method 18
4.1 Patient selection 19
4.2 Pre-treatment patient assessment 19
4.3 Tumor Staging 20
4.4 Treatment design 20
4.5 Trial Standard Operating Procedure 21
4.6 Follow up 21
4.7 Assessment of therapeutic effect 22
4.8 Adverse Effect 22
4.9 Statistical Analysis 23
Chapter V Results 24
5.1 Patient population and tumor types 25
5.2 Tumor Staging 25
5.3 Treatment effect 26
5.4 Adverse effect 27
Chapter VI Discussion 29
6.1 Treatment efficacy 30
6.1.1 Treatment Efficacy- Needle Placement 30
6.1.2 Treatment Efficacy- Modifications to needle placement 31
6.2 Adverse effects 33
6.2.1- Adverse Effect- management 35
6.3 Immune response 37
6.4 Indication for EMT 38
6.5 Limitations 39
6.6 Future prospect 39
Chapter VII Conclusion 42
Tables 44
Figures 57
References 66

1.2011. Veterinary cooperative oncology group - common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1. Vet Comp Oncol.
2.Berrocal, A., Vos, J.H., Ingh, T.S.G.A.M., Molenbeek, R.F., Sluijs, F.J., 1989. Canine Perineal Tumours. J Vet Med A 36, 739-749.
3.Borrego, J., Cartagena, J., Engel, J., 2009. Treatment of feline mammary tumours using chemotherapy, surgery and a COX‐2 inhibitor drug (meloxicam): a retrospective study of 23 cases (2002–2007)*. Vet Comp Oncol 7, 213-221.
4.Bostock, D., 1986. Neoplasms of the skin and subcutaneous tissues in dogs and cats. Brit Vet J 142, 1-19.
5.Brehm, D.M., Vite, C.H., Steinberg, H.S., Haviland, J., Van Winkle, T., 1994. A retrospective evaluation of 51 cases of peripheral nerve sheath tumors in the dog. J Am Anim Hosp Assoc 31, 349-359.
6.Brodey, R.S., 1970. Canine and feline neoplasia. Adv Vet Sci Comp Med 14, 309-354.
7.Chu, K.F., Dupuy, D.E., 2014. Thermal ablation of tumours: biological mechanisms and advances in therapy. Nat Rev Cancer 14, 199-208.
8.Cohen, M., Wright, J.C., Brawner Jr, W.R., Smith, A.N., Henderson, R., Behrend, E.N., 2001. Use of surgery and electron beam irradiation, with or without chemotherapy, for treatment of vaccine-associated sarcomas in cats: 78 cases (1996-2000). JAVMA-J Am Vet Med A 219, 1582-1589.
9.den Brok, M.H., Sutmuller, R.P., van der Voort, R., Bennink, E.J., Figdor, C.G., Ruers, T.J., Adema, G.J., 2004. In situ tumor ablation creates an antigen source for the generation of antitumor immunity. Cancer Res 64, 4024-4029.
10.Dernell, W.S., Withrow, S.J., Kuntz, C.A., Powers, B.E., 1998. Principles of treatment for soft tissue sarcoma. ClinTech Small An P 13, 59-64.
11.Dorn, C., Taylor, D., Schneider, R., Hibbard, H., Klauber, M., 1968. Survey of animal neoplasms in Alameda and Contra Costa Counties, California. II. Cancer morbidity in dogs and cats from Alameda County. J Natl Cancer I 40, 307-318.
12.Downing, S., Chien, M.B., Kass, P.H., Moore, P.F., London, C.A., 2002. Prevalence and importance of internal tandem duplications in exons 11 and 12 of c-kit in mast cell tumors of dogs. Am J Vet Res 63, 1718-1723.
13.Elpiner, A.K., Brodsky, E.M., Hazzah, T.N., Post, G.S., 2011. Single-agent gemcitabine chemotherapy in dogs with hepatocellular carcinomas. Vet Comp Oncol 9, 260-268.
14.Goldschmidt, M., Hendrick, M., 2008. Tumors of the skin and soft tissues. Tumors in Domestic Animals, Fourth Edition, 45-117.
15.Goldschmidt, M.H., Shofer, F.S., 1992. Skin tumors of the dog and cat. Pergamon Press Ltd.
16.Haen, S.P., Pereira, P.L., Salih, H.R., Rammensee, H.G., Gouttefangeas, C., 2011. More than just tumor destruction: immunomodulation by thermal ablation of cancer. Clin Dev immunol 2011, 160250.
17.Hammer, A.S., Sikkema, D.A., 1995. Hepatic Neoplasia in the Dog and Cat. Vet Clin N Am-Small 25, 419-435.
18.Harris, N.L., Jaffe, E.S., Diebold, J., Flandrin, G., Muller-Hermelink, H.K., Vardiman, J., Lister, T.A., Bloomfield, C.D., 1999. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting—Airlie House, Virginia, November 1997. J Clin Oncol 17, 3835-3849.
19.Hayes Jr, H., Milne, K., Mandell, C., 1981. Epidemiological features of feline mammary carcinoma. Vet Rec 108, 476-479.
20.Hendrick, M.J., Kass, P.H., McGill, L.D., Tizard, I.R., 1994. Postvaccinal sarcomas in cats. J Natl Cancer I 86, 341-343.
21.Huang, S.C., Chang, Y.Y., Kang, J.W., Tsai, H.W., Shan, Y.S., Lin, X.Z., Lee, G.B., 2014a. An electromagnetic thermotherapy system with a deep penetration depth for percutaneous thermal ablation. Ann Biomed Eng 42, 86-96.
22.Huang, S.C., Huang, C.H., Lin, X.Z., Lee, G.B., 2009. High Frequency Electromagnetic Thermotherapy for Cancer Treatment. 23, 574-577.
23.Huang, S.C., Kang, J.W., Tsai, H.W., Shan, Y.S., Lin, X.Z., Lee, G.B., 2014b. Electromagnetic thermotherapy system with needle arrays: a practical tool for the removal of cancerous tumors. IEEE T Bio-Med Eng 61, 598-605.
24.Ito, T., Kadosawa, T., Mochizuki, M., Matsunaga, S., Nishimura, R., Sasaki, N., 1996. Prognosis of malignant mammary tumor in 53 cats. J Vet Med Sci 58, 723-726.
25.Khatri, V.P., Goodnight, J.E., Jr., 2005. Extremity soft tissue sarcoma: controversial management issues. Surg Oncol 14, 1-9.
26.Kosovsky, J.K., Matthiesen, D.T., Marretta, S.M., Patnaik, A.K., 1991. Results of partial mandibulectomy for the treatment of oral tumors in 142 dogs. Vet Surg : VS 20, 397-401.
27.Lee, C.T., Mace, T., Repasky, E.A., 2010. Hypoxia-driven immunosuppression: a new reason to use thermal therapy in the treatment of cancer? Int J Hyperther: the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 26, 232-246.
28.Martano, M., Morello, E., Buracco, P., 2011. Feline injection-site sarcoma: past, present and future perspectives. Vet J 188, 136-141.
29.McNeill, C., Sorenmo, K., Shofer, F., Gibeon, L., Durham, A., Barber, L., Baez, J., Overley, B., 2009. Evaluation of Adjuvant Doxorubicin‐Based Chemotherapy for the Treatment of Feline Mammary Carcinoma. J Vet Intern Med 23, 123-129.
30.McSporran, K., 2009. Histologic grade predicts recurrence for marginally excised canine subcutaneous soft tissue sarcomas. Vet Pathol 46, 928-933.
31.Nielsen, S., Attosmis, J., 1964. CANINE PERIANAL GLAND TUMORS. Journal of the American Veterinary Medical Association 144, 127.
32.Owen, L.N., 1980. TNM classification of tumours in domestic animals. TNM classification of tumours in domestic animals.
33.Patnaik, A.K., Hurvitz, A.I., Lieberman, P.H., 1980. Canine Hepatic Neoplasms: A Clinicopathologic Study. Vet Pathol 17, 553-564.
34.Patnaik, A.K., Hurvitz, A.I., Lieberman, P.H., Johnson, G.F., 1981. Canine hepatocellular carcinoma. Vet Pathol 18, 427-438.
35.Repasky, E.A., Evans, S.S., Dewhirst, M.W., 2013. Temperature matters! And why it should matter to tumor immunologists. Cancer immunol Res 1, 210-216.
36.Russell, W.O., Cohen, J., Enzinger, F., Hajdu, S.I., Heise, H., Martin, R.G., Meissner, W., Miller, W.T., Schmitz, R.L., Suit, H.D., 1977. A clinical and pathological staging system for soft tissue sarcomas. Cancer 40, 1562-1570.
37.Schwegler, K., Walter, J.H., Rudolph, R., 1997. Epithelial Neoplasms of the Skin, the Cutaneous Mucosa and the Transitional Epithelium in Dogs: An Immunolocalization Study for Papillomavirus Antigen. J Vet Med A 44, 115-123.
38.Simpson, A.M., Ludwig, L.L., Newman, S.J., Bergman, P.J., Hottinger, H.A., Patnaik, A.K., 2004. Evaluation of surgical margins required for complete excision of cutaneous mast cell tumors in dogs. JAVMA-J Am Vet Med A 224, 236-240.
39.Skitzki, J.J., Repasky, E.A., Evans, S.S., 2009. Hyperthermia as an immunotherapy strategy for cancer. Curr Opin Investig Drugs 10, 550-558.
40.Zhang, H.G., Mehta, K., Cohen, P., Guha, C., 2008. Hyperthermia on immune regulation: a temperature''s story. Cancer lett 271, 191-204.
41.Zhang, Y., Zhang, W., Geng, C., Lin, T., Wang, X., Zhao, L., Tang, J., 2009. Thermal ablation versus conventional regional hyperthermia has greater anti-tumor activity against melanoma in mice by upregulating CD4+ cells and enhancing IL-2 secretion. Prog Nat Sci 19, 1699-1704.

第一頁 上一頁 下一頁 最後一頁 top